Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-C0979 in Advanced Solid Tumors
NCT07414836Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of BG-C0979 in solid tumor (4 arms), sponsored by BeOne Medicines. Primary endpoints: Adverse Events at 24 months, Maximum Tolerated Dose or Maximum Administered Dose at 10 months and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
BG-C0979
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07414836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414836.